Celltrion Completes Acquisition of Takeda Pharmaceutical's Asia-Pacific Product Assets

[Asia Economy Reporter Cho Hyun-ui] Celltrion has completed the acquisition of rights and assets for Takeda Pharmaceutical's Asia-Pacific product portfolio.

On the 1st, Celltrion announced this and stated, "The acquisition was carried out through our newly established subsidiary in Singapore, ‘Celltrion Asia-Pacific.’"

Earlier in June, Celltrion announced that it would acquire 18 product assets of Takeda Pharmaceutical's Asia-Pacific ‘Primary Care’ portfolio for $278.3 million (approximately 307.4 billion KRW).

Through this acquisition, Celltrion APAC can now directly and indirectly exercise rights related to patents, trademarks, approvals, and sales of 18 products sold in nine markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.

The acquired product portfolio includes prescription drugs such as Nesina and Actos (diabetes treatments), Idalbi (hypertension treatment), as well as over-the-counter drugs like Pyeongwhae-tuben (cold medicine) and Albocil (stomatitis treatment).

Celltrion stated, "This acquisition provides an opportunity to domestically produce essential medicines that were previously dependent on imports," adding, "We will accelerate the development of improved new drugs and insulin biosimilars to complete our diabetes and hypertension product portfolio."

Production will utilize Takeda’s existing manufacturers to ensure stable product supply. Subsequently, some products will be manufactured at Celltrion Pharm’s cGMP (current Good Manufacturing Practice) facilities for domestic and international sales. Celltrion Pharm will handle sales in the Korean market, while Celltrion Healthcare will leverage its existing sales network for global market sales.

A Celltrion official said, "We will do our best in research and development (R&D) and contract development and manufacturing organization (CDMO) businesses in the Asia-Pacific region to grow into a global integrated pharmaceutical and bio company," adding, "We plan to gradually expand our business to include establishing cold chain distribution networks for biopharmaceuticals in the Asia-Pacific region, overseeing product distribution and sales management."

This content was produced with the assistance of AI translation services.